See more : McCoy Global Inc. (MCCRF) Income Statement Analysis – Financial Results
Complete financial analysis of Ovation Science Inc. (OVAT.CN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ovation Science Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Golan Plastic Products Ltd (GLPL.TA) Income Statement Analysis – Financial Results
- Reata Pharmaceuticals, Inc. (RETA) Income Statement Analysis – Financial Results
- Murphy Oil Corporation (MUR) Income Statement Analysis – Financial Results
- Grand Foundry Limited (GFSTEELS.NS) Income Statement Analysis – Financial Results
- TESEC Corporation (6337.T) Income Statement Analysis – Financial Results
Ovation Science Inc. (OVAT.CN)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://ovationscience.com
About Ovation Science Inc.
Ovation Science Inc. engages in the production of cannabis or hemp products in Canada, the United States, and Mexico. The company's Invisicare is a patented drug delivery technology for use in topical and transdermal skin care products containing hemp seed oil and cannabis under the Ovation and BASKiN brands. It offers cannabidiol infused health and wellness solutions under the Invibe MD name; skincare solutions under the ARLO CBD name; and hand sanitizers under the DermSafe name. The company holds sublicenses for cannabis based products; and Lighthouse for licensed dispensaries in the United States. Ovation Science Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
---|---|---|---|---|---|---|---|
Revenue | 61.93K | 138.15K | 224.95K | 750.01K | 302.38K | 96.41K | 12.55K |
Cost of Revenue | 7.83K | 2.98K | 36.95K | 201.99K | 18.45K | 13.92K | -17.56K |
Gross Profit | 54.10K | 135.18K | 188.00K | 548.02K | 283.93K | 82.49K | 30.11K |
Gross Profit Ratio | 87.35% | 97.85% | 83.57% | 73.07% | 93.90% | 85.56% | 240.00% |
Research & Development | 8.79K | 65.27K | 83.07K | 130.40K | 80.05K | 63.88K | 0.00 |
General & Administrative | 458.48K | 427.80K | 892.31K | 1.47M | 922.22K | 371.71K | 152.73K |
Selling & Marketing | 14.13K | 19.93K | 33.72K | 26.56K | 138.27K | 59.62K | -89.09K |
SG&A | 472.61K | 447.73K | 926.04K | 1.50M | 1.06M | 431.33K | 63.64K |
Other Expenses | -427.30K | 414.54K | 8.02K | 8.61K | 2.57K | 0.00 | 0.00 |
Operating Expenses | 54.10K | 927.54K | 1.02M | 1.64M | 1.14M | 495.21K | 63.64K |
Cost & Expenses | 825.94K | 930.52K | 1.05M | 1.84M | 1.16M | 509.12K | 63.64K |
Interest Income | 0.00 | 3.00 | 4.72K | 13.54K | 24.87K | 3.03K | 20.73K |
Interest Expense | 31.08K | 588.00 | 0.00 | 15.65K | 34.08K | 43.06K | 0.00 |
Depreciation & Amortization | 3.24K | 6.73K | 8.02K | 8.61K | 2.57K | 412.71K | 122.62K |
EBITDA | -778.83K | -786.73K | -2.39M | -1.16M | -799.30K | -409.69K | 69.72K |
EBITDA Ratio | -1,257.52% | -568.66% | -355.79% | -142.16% | -275.06% | -424.95% | -199.90% |
Operating Income | -764.01K | -792.36K | -808.36K | -1.07M | -834.31K | -412.71K | -51.09K |
Operating Income Ratio | -1,233.58% | -573.54% | -359.35% | -143.31% | -275.91% | -428.09% | -407.25% |
Total Other Income/Expenses | -49.14K | -55.37K | -877.29K | -250.05K | -1.63K | -95.69K | -96.61K |
Income Before Tax | -813.15K | -794.05K | -2.39M | -1.18M | -835.94K | -508.40K | -61.54K |
Income Before Tax Ratio | -1,312.93% | -574.76% | -1,064.14% | -157.98% | -276.45% | -527.35% | -490.56% |
Income Tax Expense | 0.00 | 1.10K | 16.05K | 15.65K | 34.08K | 52.63K | -96.61K |
Net Income | -813.15K | -795.15K | -2.41M | -1.20M | -870.02K | -508.40K | -61.54K |
Net Income Ratio | -1,312.93% | -575.56% | -1,071.28% | -160.07% | -287.72% | -527.35% | -490.56% |
EPS | -0.03 | -0.03 | -0.08 | -0.05 | -0.05 | -0.03 | 0.00 |
EPS Diluted | -0.03 | -0.03 | -0.08 | -0.05 | -0.05 | -0.03 | 0.00 |
Weighted Avg Shares Out | 30.32M | 29.37M | 29.37M | 26.67M | 16.17M | 16.12M | 23.15M |
Weighted Avg Shares Out (Dil) | 30.32M | 29.37M | 29.37M | 26.67M | 16.17M | 16.12M | 23.15M |
Source: https://incomestatements.info
Category: Stock Reports